MedTrace Logo

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

NCT00207103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2008-11-04

No results posted yet for this study

Summary

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

Brivanib

Tablets, Oral, 180 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 320 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 600 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression

DRUG

Brivanab

Tablets, Oral, 1000 mg, once daily, until disease progression

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2007-10-31
Completion
2008-09-30

Countries

  • United States
  • Canada
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207103 on ClinicalTrials.gov